AusAm Biotechnologies Inc.
This article was originally published in Start Up
Executive Summary
Three-year-old AusAm Biotechnologies is actively pursuing both diagnostics and therapeutics, with all novel technologies based on its founding scientists' observations about the kidney. In diagnostics, it recently received FDA clearance for a highly sensitive test that detects precursors to kidney disease. The test has potential to become a wide screen, particularly for at-risk diabetics. In therapeutics, it is developing a polysaccharide-based class of anti-viral attachment inhibitors, which have potential in treatment of infectious diseases like AIDs, encephalitis and small pox.